■ 研究業績 ○ 論文 原著論文（英文） 1. Mitsukura Y, Tazawa Y, Nakamura R, Sumali B, Nakagawa T, Hori S, Mimura M, Kishimoto T. Characteristics of single-channel electroencephalogram in depression during conversation with noise reduction technology. PLoS One. 2022 Apr 13;17(4):e0266518. 2. Mikami R, Hayakawa M, Imai S, Sugawara M, Takekuma Y. Onset timing and duration of augmented renal clearance in a mixed intensive care unit. J Intensive Care. 2023 Mar 23;11(1):13. Iino H, Hashiguchi M, Hori S. Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review. PLoS One. 2022 Apr 14;17(4):e0266934. 3. 4. Kizaki H, Yamamoto D, Satoh H, Masuko K, Maki H, Konishi Y, Hori S, Sawada Y. Analysis of contributory factors to incidents related to medication assistance for residents taking medicines in residential care homes for the elderly: a qualitative interview survey with care home staff. BMC Geriatr. 2022 Apr 22;22(1):352. 5. Nishioka S, Watanabe T, Asano M, Yamamoto T, Kawakami K, Yada S, Aramaki E, Yajima H, Kizaki H, Hori S. Identification of hand-foot syndrome from cancer patients' blog posts: BERT-based deep-learning approach to detect potential adverse drug reaction symptoms. PLoS One. 2022 May 4;17(5):e0267901. 6. Watanabe T, Yada S, Aramaki E, Yajima H, Kizaki H, Hori S. Extracting Multiple Worries From Breast Cancer Patient Blogs Using Multilabel Classification With the Natural Language Processing Model Bidirectional Encoder Representations From Transformers: Infodemiology Study of Blogs. JMIR Cancer. 2022 Jun 3;8(2):e37840. 7. Kaseda D, Hashiguchi M, Kizaki H, Hori S. Latent class analysis of patients' background factors affecting the risk of specific adverse drug reactions to dipeptidyl peptidase 4 inhibitors. Int J Clin Pharmacol Ther. 2022 Aug;60(8):346-357. Ikegami K, Hashiguchi M, Kizaki H, Yasumuro O, Funakoshi R, Hori S. Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D3 )/Calcium Supplement. J Clin Pharmacol. 2022 Sep;62(9):1151-1159. 8. 9. Okada T, Hashiguchi M, Hori S. Classification of patient characteristics associated with reported adverse drug events to neuraminidase inhibitors: an applicability study of latent class analysis in pharmacovigilance. Int J Clin Pharm. 2022 Dec;44(6):1332-1341. 10. Miyai T, Imai S, Yoshimura E, Kashiwagi H, Sato Y, Ueno H, Takekuma Y, Sugawara M. Machine learning-based model for estimating vancomycin maintenance dose to target the area under the concentration curve of 400-600 mg・h/L in Japanese patients. Biol pharm bull. 2022 45(9):1332-1339. 11. Imai S, Mitsuboshi S, Hori S, Suzuki S. Increased risk of Lambert-Eaton myasthenic syndrome (LEMS) in small-cell lung cancer patients treated with immune checkpoint inhibitor. Eur J Cancer. 2023 Feb;180:1-3. 12. Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K, Iba C, Shibata M, Takemura R, Hori S, Nakahara J. Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol. 2022 Dec 31;22(1):512. 医薬品情報学講座■■ 医薬品情報学講座 133
元のページ ../index.html#137